CTRI Number |
CTRI/2020/04/024833 [Registered on: 24/04/2020] Trial Registered Prospectively |
Last Modified On: |
01/06/2020 |
Post Graduate Thesis |
No |
Type of Trial |
Interventional |
Type of Study
|
Vaccine |
Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
Public Title of Study
|
BCG-Denmark versus no-BCG for COVID 19 prevention |
Scientific Title of Study
|
Effect of BCG-Denmark (Green Signal) on prevention of COVID 19 infection in health care workers – a double blind randomized controlled trial |
Secondary IDs if Any
|
Secondary ID |
Registry |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Narayanan Parameswaran |
Address |
Department of Paediatrics, Women and Children Hospital,JIPMER,
Dhanvantari Nagar P.O. Dhanvantari Nagar, Puducherry Pondicherry PONDICHERRY 605006 India |
Phone |
9443458850 |
Fax |
|
Email |
narayanan.p@jipmer.edu.in |
|
Details Contact Person Scientific Query
|
Name |
Narayanan Parameswaran |
Address |
Department of Paediatrics, Women and Children Hospital,JIPMER,
Dhanvantari Nagar P.O. Dhanvantari Nagar, Puducherry Pondicherry PONDICHERRY 605006 India |
Phone |
9443458850 |
Fax |
|
Email |
narayanan.p@jipmer.edu.in |
|
Details Contact Person Public Query
|
Name |
Narayanan Parameswaran |
Address |
Department of Paediatrics, Women and Children Hospital,JIPMER,
Dhanvantari Nagar P.O. Dhanvantari Nagar, Puducherry Pondicherry PONDICHERRY 605006 India |
Phone |
9443458850 |
Fax |
|
Email |
narayanan.p@jipmer.edu.in |
|
Source of Monetary or Material Support
|
Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry |
|
Primary Sponsor
Modification(s)
|
Name |
Dr Narayanan Parameswaran |
Address |
Professor, Department of Paediatrics, JIPMER, Dhanvantari Nagar, Puducherry-605006 |
Type of Sponsor |
Other [Self] |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Contact Person |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Narayanan Parameswaran |
Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry |
Dhanvantari Nagar P.O., Puducherry -605006 Pondicherry |
9443458850
narayanan.p@jipmer.edu.in |
|
Details of Ethics Committee
Modification(s)
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Institute Ethics Committee for Interventional studies |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Healthy Human Volunteers |
Health care workers posted in Covid-19 area to take care of patients with covid-19 |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Intervention |
BCG-Denmark (Green Signal) |
BCG-Denmark (Green Signal), 0.1 ml, intradermal injection in left deltoid area |
Comparator Agent |
Placebo |
Normal saline, 0.1 ml administered intradermally in the deltoid area of left arm |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
65.00 Year(s) |
Gender |
Both |
Details |
1. All HCWs (doctors and nurses and housekeeping staff) posted to take care of patients in the designated COVID 19 wards / ICUs for at least one shift (minimum 6 hours).
2. All HCWs (doctors and nurses and housekeeping staff) likely to be posted in Emergency medical services (EMS) for one week (minimum 56 hours).
3. All laboratory workers likely to be posted for at least one week in a Virology laboratory where SARS-CoV-2 testing is being performed.
|
|
ExclusionCriteria |
Details |
1.HCWs not directly involved in patient care (facility manager, supervisory staff not physically present in the patient care areas)
2. A immunodeficiency state (including primary immunodeficiency, HIV infection, chemotherapy or high-dose steroid therapy (more than or equal to 20 mg for more than or equal to 2 weeks),non-biological immunosuppressant (also known as DMARDS), biological agents (such as monoclonal antibodies against tumor necrosis factor (TNF)-alpha)
3. Pregnancy
4.Malignancy
5.Active skin disease such as eczema, dermatitis or psoriasis at or near the site of vaccination.
6.Previously had a SARS-CoV-2 positive test result
7.BCG vaccine received in the past one year
|
|
Method of Generating Random Sequence
|
Stratified block randomization |
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
Blinding/Masking
|
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded |
Primary Outcome
|
Outcome |
TimePoints |
Proportion of HCW with symptomatic COVID 19 disease 6 months after randomization. Symptomatic COVID 19 will be defined as self-reported fever or cough, or shortness of breath, or respiratory distress, or runny or blocked nose plus a positive PCR test and/or antibody test |
Six months after randomisation |
|
Secondary Outcome
|
Outcome |
TimePoints |
Any adverse effects of intervention (BCG adenitis, disseminated BCG etc) |
Six months after randomisation |
Mortality if any due to COVID 19 disease |
Six months after randomisation |
Proportion of HCWs who develop any type of SARS-CoV-2 infection (both asymptomatic and symptomatic) |
Six months after randomisation |
Proportion of HCWs with Pneumonia (mild and severe) and ARDS requiring hospitalization due to SARS-CoV-2 |
Six months after randomisation |
|
Target Sample Size
|
Total Sample Size="1826" Sample Size from India="1826" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
01/05/2020 |
Date of First Enrollment (Global) |
No Date Specified |
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
|
Not Applicable |
Recruitment Status of Trial (India) |
Not Yet Recruiting |
Publication Details
|
Study protocol not published. Recruitment not yet started |
Brief Summary
|
WHO has declared COVID 19 as a pandemic on 11th March 2020. In addition to the high mortality around the world observed among elderly population and those with chronic comorbidities, exposure of healthcare workers (HCW) to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a major concern. In China, more than 3300 HCWs had been infected as of early March 2020 and at least 22 had died. Similarly, in Italy, 20% of frontline HCWs were infected. These figures are alarming as a shortage of HCWs can seriously impede the ability of a country to effectively manage this pandemic. The risk factors for infection in HCWs reported include working in high-risk departments, longer duty hours, and suboptimal hand hygiene after contact with patients. Though some of these risk factors are modifiable, we need to implement all possible strategies to decrease the risk of COVID 19 infection to HCWs. In this context, one promising intervention could be Bacillus Calmette-Guerin vaccine (BCG) vaccination. A couple of recent ecological studies have suggested a possible association between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19 at country level. However, these observations need confirmation in randomised clinical trials. Live attenuated
vaccines, such as measles vaccine, BCG and oral polio vaccine (OPV), have
beneficial effects beyond protection
against the targeted infections, through induction of non-specific immunity that
protects the recipients from other infections. This observation has been
confirmed by several randomized controlled trials. In three randomised trials
in low-birth-weight infants, BCG-Denmark reduced neonatal mortality by 38% (95%
CI, 17%-54%) in Guinea-Bissau. A meta-analysis of the 3 RCTs of early BCG
supported marked reductions in mortality within 3 days after vaccination, and
at 28 days and 12 months of age. Further, in a randomised trial in
South Africa, revaccination with BCG-Denmark besides reducing sustained
tuberculosis infections by 45% (95% CI, 6.4%-68.1%), also reduced the incidence of upper respiratory tract
infections by 73% (39%-88%) and all infections by 57% (28%-74%). A recent review by Moorlag et al
has specifically looked at the nonspecific effects of BCG on viral infections
including influenza A, HPV, RSV in humans as well as animals. Human
studies with BCG showed the recipients having decreased episodes of genital
herpes infection, improved clearance of viral warts, and enhanced antibody
production with influenza A vaccine. Animal studies reviewed had shown the ability
of BCG to offer protection against HSV1, Japanese encephalitis, encephalomyocarditis
etc. If this beneficial effect of BCG can be proven to be true, administration of BCG may be used as a novel strategy to protect against viral infections, especially against those infections that cause global pandemics and for which an effective vaccine is currently not available. The potential for this to save the life of millions of people is exciting. Our study hypothesis is that administration of a single dose of BCG vaccine to health care workers reduce the risk of development of COVID 19 disease in them. |